Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

50.22 +3.52 (+7.54%)
Streaming Delayed Price Updated: 11:51 AM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
From Veracyte, Inc.
Via Business Wire
News headline image
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
News headline image
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
From Veracyte, Inc.
Via Business Wire
Expert Ratings for Veracyte ↗
 
Via Benzinga
News headline image
Better Long-Term Buy in 2023: Exact Sciences or Veracyte? ↗
As cancer screenings are becoming covered more often, both companies stand to gain. 
Via The Motley Fool
News headline image
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
From Exagen Inc.
Via GlobeNewswire
News headline image
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock ↗
 
Via Benzinga
News headline image
This Small-Cap Stock Is a No-Brainer Buy ↗
This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year. 
Via The Motley Fool
News headline image
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 ↗
 
Via Benzinga
News headline image
Veracyte Stock Showing Market Leadership; Earns 93 RS Rating ↗
Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
 
Via Benzinga
News headline image
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday ↗
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry. 
Via Benzinga
News headline image
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session ↗
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. 
Via Benzinga
News headline image
US Stocks Open Lower; Nasdaq Drops 100 Points ↗
U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Thursday. The Federal Reserve, on Wednesday, raised interest rates by 75 bps. 
Via Benzinga
News headline image
Veracyte Announces Third Quarter 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
From Veracyte, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 2, 2022 ↗
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter. 
Via Benzinga
News headline image
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million. 
Via Benzinga
News headline image
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
From Veracyte, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.